Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
Thomas E. Witzig(WinnMed), Christine A. White(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Brad Pohlman(Cleveland Clinic), Christos Emmanouilides(Interbalkan Medical Center), Gregory A. Wiseman(Mayo Clinic), Robin Joyce(Beth Israel Deaconess Medical Center), Pratik S. Multani(Ignyta (United States)), Norman M. Padre(Robert H. Lurie Comprehensive Cancer Center of Northwestern University), Fernando Cabanillas(University of Puerto Rico, Medical Sciences Campus), Nancy L. Bartlett(Washington University in St. Louis), Antonio J Grillo-López(Roche (Switzerland)), Myron S. Czuczman(Roswell Park Comprehensive Cancer Center), Leo I. Gordon(Northwestern University)
Cited by 1,170
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k